Skip to main content

M28z1XXPD1DNR CAR

Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

  • RegistryNCT06623396
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMesothelin-Expressing Tumors
  • SponsorMemorial Sloan Kettering Cancer Center
How M28z1XXPD1DNR CAR worksNCT066233961 min

What the film says

Read the transcript

When stomach or esophageal cancer spreads across the lining of the abdomen, chemotherapy reaches it poorly, and survival is measured in months.

The idea: put engineered T cells directly into the abdominal cavity, and armor them against the tumor's off switch.

Most of these tumors carry mesothelin on their surface. At Memorial Sloan Kettering, a patient's own T cells receive a receptor for mesothelin, tuned to fire without exhausting, plus a decoy PD-1 receptor: it catches the tumor's shut-down signal but cannot pass it on. The cells are infused into the peritoneal cavity, where the disease is, rather than into a vein.

An early dose-finding study for metastatic esophagogastric adenocarcinoma with peritoneal spread. Geoffrey Ku leads it. Public record; not medical advice.

Sources behind this film

The drug

What is being tested.

Participants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.

The study

How the trial runs.

Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Diagnosis of pathologically confirmed EG adenocarcinoma
  • Diagnosis of metastatic or recurrent disease
  • ECOG performance status of 0-1
  • Life expectancy of ≥4 months
  • Inclusion Criteria for Leukapheresis:
  • Written informed consent for the study (from participant)

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.